Open access
Open access
Powered by Google Translator Translator

Clinical Trial Update | Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer

16 May, 2023 | 14:25h | UTC

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study – Journal of Clinical Oncology

Commentaries:

At 5-Year Follow-Up, Benefits of Pembrolizumab on Clinical Outcomes in Squamous NSCLC Maintained – ASCO Daily News

Addition of Pembrolizumab to Chemotherapy in First-Line Treatment of Metastatic Squamous NSCLC: 5-Year Update of KEYNOTE-407 – The ASCO Post

Original Study: Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer – New England Journal of Medicine

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.